Navigation Links
Obstetrics and Gynecology Publishes Data From Pivotal Phase 3 LYSTEDA Study
Date:10/6/2010

PARSIPPANY, N.J., Oct. 6 /PRNewswire/ -- Ferring Pharmaceuticals Inc. today announced publication of one of its pivotal Phase 3 trials of LYSTEDA™ (tranexamic acid) tablets for cyclic heavy menstrual bleeding (HMB) in the October issue of the peer-reviewed journal, Obstetrics & Gynecology.  The six-month clinical trial demonstrated that LYSTEDA significantly reduced menstrual blood loss from baseline, and improved health-related quality-of-life parameters in women with cyclic HMB while maintaining safety and tolerability.  It is estimated that up to 22 million women suffer from HMB in the U.S.(1,2)

In the double-blind, placebo-controlled 6-month study, women ages 18-49 years with HMB, defined as mean menstrual blood loss of 80 mL or more per cycle, were randomized to receive LYSTEDA (3.9 g/d) (n=115) or placebo (n=72) for up to 5 days per menstrual cycle through six cycles.  The LYSTEDA group had a significantly greater reduction in menstrual blood loss of 69.6 mL (40.4%) compared with 12.6 mL (8.2%) in the placebo group (p<.001).  This reduction in menstrual blood loss was considered meaningful to women.  Women taking LYSTEDA also experienced significant improvements in limitations in social, leisure and physical activities, measured using the Menorrhagia Impact Questionnaire (MIQ), a validated patient-reported outcome instrument, to measure changes at baseline and after three treatment menstrual cycles.

LYSTEDA was generally well tolerated, and the majority of adverse events were mild to moderate in severity.  The most common adverse events reported were menstrual discomfort or cramps, headache, and back pain.

"We are excited by the results of this clinical trial.  Women receiving LYSTEDA met all three primary efficacy points: a significantly greater reduction in menstrual blood loss compared with placebo, a reduction exceeding a pre-specified volume, and most importantly, a reduction
'/>"/>

SOURCE Ferring Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Boston Scientifics Urology/Gynecology Products Featured in Studies at Global Congress
2. Siemens Healthcare Diagnostics Publishes Global Trade Item Numbers (GTINs) for its Entire U.S. Product Line to the GHX Health ConneXion(SM) Data Pool
3. The ASCO Post Publishes Multiple Perspectives on Outcome of ODAC Meeting Regarding Bevacizumab in Advanced Breast Cancer
4. The New England Journal of Medicine Publishes Results of Landmark CREST Study, Showing Similar Positive Outcomes for Abbotts Carotid Stent System and Surgery
5. The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes
6. BioTrends Publishes New Report Exploring Treatment Patterns for Anemia Across a Variety of Physician Specialties
7. NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses
8. BIA Publishes White Paper: ISO 9000 Role in Document Review, Emphasizes Quality Equals Defensibility
9. United States Patent and Trademark Office Publishes Stemedicas Patent Application for the Treatment of Diabetic Retinopathy
10. The Lancet Publishes Direct Comparison Study Between Liraglutide and Exenatide
11. The Lancet Publishes Two-Year Results of Abbotts Fully Bioabsorbable Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)...  Uroplasty, Inc. (NASDAQ: UPI ), a medical device ... to treat voiding dysfunctions, today reported financial results for ... Global revenue for the Company,s Urgent ®  PC ... quarterly revenue record, as compared to $3.9 million in ...
(Date:1/22/2015)... 22, 2015  Amgen (NASDAQ: AMGN ) today announced that ... results on Tuesday, Jan. 27, 2015, after the close of the ... call with the investment community at 2 p.m. PT. Participating in ... chairman and chief executive officer, and other members of Amgen,s senior ...
(Date:1/22/2015)... , Jan. 22, 2015 Increasing sophistication among enterprise ... of localization purchasing in 2015, says Moravia ... a recent study by market research firm Common Sense ... solution for their translation and localization needs. "From a ...
Breaking Medicine Technology:Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2
... on Glucose Homeostasis Effects in,Normal and Diabetic Rats ... a 14-day,Phase IIa study of the safety profile ... selective inhibitor of,the Sodium-Glucose Transporter 2 (SGLT2) administered ... 2 diabetes, no,discontinuations due to adverse events and ...
... LOUISVILLE, Colo., June 26, 2007 /PRNewswire-FirstCall/ --,Replidyne, ... I trials,studying REP8839, a novel topical antibiotic ... major skin pathogens including,methicillin-resistant S. aureus (MRSA). ... that topically applied REP8839 appears safe,well-tolerated and ...
Cached Medicine Technology:First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 2First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 3First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 4First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 5First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 6Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 2Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 3Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 4
(Date:1/22/2015)... York (PRWEB) January 22, 2015 Thousand ... Fresenius Medical Care recalled its GranuFlo and NaturaLyte dialysis ... litigation underway in U.S. District Court, District of Massachusetts, ... January 20th, the Court has remanded a case filed ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 For over 20 years, ... Oceanside and Vista area has treated just about every ... personal injury circumstances. And for those same twenty-plus years, the ... of all those injuries with the best possible doctor. ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Joan Lunden, ... keynote speaker at the upcoming 32nd Annual Miami ... Physicians’ Education Resource®, LLC (PER®) , shares that ... have gone undetected if she had not followed up ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Yesterday, ... Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were honored ... leadership in advancing biotechnology, biomedical science, medical device ... Olsen each received the “2014 Life Sciences Champion” ...
(Date:1/22/2015)... Florida (PRWEB) January 22, 2015 IsoComforter, Inc. ... therapy machine with patented IsoTube design to treat specific body ... introduced the most progressive and easy to use patented cold ... post-operative and sports related orthopedic and muscle injuries. IsoComforter ...
Breaking Medicine News(10 mins):Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
... National leaders are meeting in Washington for the National ... urge Congress to support healthcare reform and address the ... nation,s largest populations -- baby boomers and Hispanics -- ... decision-makers, experts and academic leaders will meet for the ...
... The American Federation of Government Employees today told ... on private for-profit health care providers is straining medical ... 180,000 employees on the frontlines of the Department of ... one of the many tools available to the VA ...
... In a first-of its-kind study, epidemiologists at the University of Pennsylvania ... those who possessed them from being shot in an assault. ... more likely to be shot in an assault than those not ... month in the American Journal of Public Health , in ...
... Transition from ... ... More than 42,000 male and female swimmers have competed at Division 1 universities in the ... new study, published in the October issue of the American Journal of Sports Medicine ...
... , FORT WORTH, Texas, Sept. 30 DSS Research ... combines solid science and proven tools into a single ... regarding physical and mental health, preventive care and current ... this tool, members are categorized from low to high ...
... 30 According to a new,healthcare market research report ... published by MarketsandMarkets,( http://www.marketsandmarkets.com ), in 2009, the entire ... be approximately $159.6,billion. Home healthcare service market is estimated ... of the entire market. , ...
Cached Medicine News:Health News:National Hispanic Council on Aging Urges Healthcare Reform and Geriatrics Training for Health Professionals as Older Americans Reach 20% of Population 2Health News:National Hispanic Council on Aging Urges Healthcare Reform and Geriatrics Training for Health Professionals as Older Americans Reach 20% of Population 3Health News:For-Profit Health Care Contracts Jeopardizing the Strength of the VA, Union Says 2Health News:For-Profit Health Care Contracts Jeopardizing the Strength of the VA, Union Says 3Health News:Penn study asks, protection or peril? Gun possession of questionable value in an assault 2Health News:New Study Highlights Injury Patterns in Collegiate Swimmers 2Health News:DSS Research Announces Senior Health Risk Assessment (SrHRA)(TM) 2Health News:MarketsandMarkets: Global Home health Care Market Worth US$159.6 Billion by 2014 2Health News:MarketsandMarkets: Global Home health Care Market Worth US$159.6 Billion by 2014 3
The flexible EXXCEL ePTFE Vascular Access Graft material is designed to offer textile-like handling characteristics-cuts neatly for a clean edge, retains fully open lumen shape, and sutures smoothly....
... intended for monitoring the accuracy and precision of ... in vitro diagnostic use only. Provided in a ... up to ten days stability at 2 ... used in accordance with the directions accompanying the ...
PowerMed is a billing software....
Managed care is a billing and tracking system....
Medicine Products: